CALU

Across TCGA pan-cancer cohorts, CALU Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CALU data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CALU Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CALU expression acts as an unfavorable survival marker.

ESCA, BLCA, and PRAD are the cancer types where CALU Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.102	0.703	<.001	36	view →
BLCA	OS	Median	III,IV	0.188	0.654	.015	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CALU–ESCA (OS)

Open the ESCA breakdown →